Ribociclib: beside a new treatment under test

44 studies: a new drug, cell therapy or vaccine is what the study tests. Page 1 of 1. Open to participants first (22), then studies with results posted, then the rest; newest registration first within each.

QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant ChemotherapyNot yet recruitingNCT07782840Phase 2 Report a problem
A Study to Evaluate ATX-898 in Participants With Advanced Solid TumorsRecruitingNCT07767474Phase 1/2 Report a problem
A Phase IIIb Study to Evaluate Camizestrant Plus Ribociclib in ER-positive, HER2-negative Advanced Breast CancerRecruitingNCT07647328Phase 3 Report a problem
A Study to Investigate the Efficacy and Safety of Letrozole SIE Compared With Femara® (Both Combined With the CDK4/6 Inhibitor Ribociclib) in Postmenopausal Women With HR-Positive, HER2-Negative, Inoperable Locally Advanced or Metastatic Breast CancerNot yet recruitingNCT07340658Phase 3 Report a problem
Efficacy and Safety of Camizestrant Plus Ribociclib in Patients With Breast CancerRecruitingNCT07195227Phase 2 Report a problem
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast CancerRecruitingNCT07180160Phase 2 Report a problem
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)RecruitingNCT07174336Phase 3 Report a problem
A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast CancerNot yet recruitingNCT07173556Phase 1/2 Report a problem
Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerRecruitingNCT07085767Phase 3 Report a problem
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast CancerRecruitingNCT07054190Phase 2 Report a problem
Efficacy and Safety of Trastuzumab Rezetecan Followed by CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2-Low/Ultra-Low Advanced Breast CancerRecruitingNCT07037199Phase 2 Report a problem
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BCRecruitingNCT07002177Phase 1/2 Report a problem
Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid TumorsRecruitingNCT06726148Phase 1/2 Report a problem
Open-Label Study of BBO-10203 in Subjects With Advanced Solid TumorsRecruitingNCT06625775Phase 1 Report a problem
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast CancerRecruitingNCT06380751Phase 3 Report a problem
Study of AVZO-021 in Patients With Advanced Solid TumorsRecruitingNCT05867251Phase 1/2 Report a problem
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid TumorsRecruitingNCT05768139Phase 1/2 Report a problem
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast CancerRecruitingNCT05683418Phase 1 Report a problem
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast CancerRecruitingNCT05216432Phase 1 Report a problem
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast CancerRecruitingNCT04802759Phase 1/2 Report a problem
A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2 Report a problem
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Metastatic or Locally Advanced Breast CancerRecruitingNCT03424005Phase 1/2 Report a problem
Phase 1b/2 Study of TTI-101 in Combination for Patients With Metastatic Hormone Receptor-Positive and HER2-Negative Breast CancerTerminatedNCT05384119Phase 1Results posted Report a problem
Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaCompletedNCT03484923Phase 2Results posted Report a problem
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast CancerActive, not recruitingNCT06239467Phase 1 Report a problem
A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid TumorsActive, not recruitingNCT06188520Phase 1/2 Report a problem
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)Active, not recruitingNCT06065748Phase 3 Report a problem
[177Lu]Lu-NeoB in Combination With Ribociclib and Fulvestrant in Participants With ER+, HER2- and GRPR+ Advanced Breast CancerActive, not recruitingNCT05870579Phase 1 Report a problem
First-in-Human Study of RLY-5836 in Advanced Breast Cancer and Other Solid TumorsCompletedNCT05759949Phase 1 Report a problem
TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study B)TerminatedNCT05573555Phase 1/2 Report a problem
Phase 1b Study of OP-1250 (Palazestrant) in Combination With Ribociclib, Alpelisib, Everolimus, or Atirmociclib in ER+, HER2- Breast CancerActive, not recruitingNCT05508906Phase 1 Report a problem
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C MutationTerminatedNCT05358249Phase 1/2 Report a problem
(VELA) Study of BLU-222 in Advanced Solid TumorsTerminatedNCT05252416Phase 1 Report a problem
Study of INCB123667 in Subjects With Advanced Solid TumorsActive, not recruitingNCT05238922Phase 1 Report a problem
Phase III Study to Assess AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression (SERENA-6)Active, not recruitingNCT04964934Phase 3 Report a problem
Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)Active, not recruitingNCT04862663Phase 3 Report a problem
Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic MelanomaActive, not recruitingNCT04417621Phase 2 Report a problem
Ribociclib and Spartalizumab in R/M HNSCCStatus unknownNCT04213404Phase 1 Report a problem
Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected MalignanciesTerminatedNCT04000529Phase 1 Report a problem
Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.Active, not recruitingNCT03616587Phase 1 Report a problem
Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLCActive, not recruitingNCT03333343Phase 1 Report a problem
Ribociclib + PDR001 in Breast Cancer and Ovarian CancerTerminatedNCT03294694Phase 1 Report a problem
A Phase Ib Study of LXH254-centric Combinations in NSCLC or MelanomaTerminatedNCT02974725Phase 1 Report a problem
Phase I/Ib Trial of LSZ102 Single Agent or LSZ102 + LEE011 or LSZ102 + BYL719 in ER+ Breast CancersTerminatedNCT02734615Phase 1 Report a problem

← Ribociclib